| A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants RTS, S Clinical Trials Partnership New England Journal of Medicine 367 (24), 2284-2295, 2012 | 1474* | 2012 |
| Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised … S Rts Lancet 386 (9988), 31-45, 2015 | 1021 | 2015 |
| Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10 AHJ van den Biggelaar, R van Ree, LC Rodrigues, B Lell, AM Deelder, ... The Lancet 356 (9243), 1723-1727, 2000 | 916 | 2000 |
| Phase 1 trials of rVSV Ebola vaccine in Africa and Europe ST Agnandji, A Huttner, ME Zinser, P Njuguna, C Dahlke, JF Fernandes, ... New England Journal of Medicine 374 (17), 1647-1660, 2016 | 509 | 2016 |
| Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine DE Neafsey, M Juraska, T Bedford, D Benkeser, C Valim, A Griggs, ... New England Journal of Medicine 373 (21), 2025-2037, 2015 | 428 | 2015 |
| Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial M Adjuik, P Agnamey, A Babiker, S Borrmann, P Brasseur, M Cisse, ... The Lancet 359 (9315), 1365-1372, 2002 | 408 | 2002 |
| Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial MT White, R Verity, JT Griffin, KP Asante, S Owusu-Agyei, B Greenwood, ... The Lancet infectious diseases 15 (12), 1450-1458, 2015 | 350 | 2015 |
| Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites RTS, S Clinical Trials Partnership (2014) PLoS medicine 11 (7), e1001685, 2014 | 350 | 2014 |
| Interferon-γ Responses Are Associated with Resistance to Reinfection with Plasmodium falciparum in Young African Children AJF Luty, B Lell, R Schmidt-Ott, LG Lehman, D Luckner, B Greve, ... The Journal of infectious diseases 179 (4), 980-988, 1999 | 328 | 1999 |
| Low Interleukin-12 Activity in Severe Plasmodium falciparum Malaria AJF Luty, DJ Perkins, B Lell, R Schmidt-Ott, LG Lehman, D Luckner, ... Infection and immunity 68 (7), 3909-3915, 2000 | 319 | 2000 |
| Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled … JJ Aponte, D Schellenberg, A Egan, A Breckenridge, I Carneiro, ... The Lancet 374 (9700), 1533-1542, 2009 | 304 | 2009 |
| Fosmidomycin, a novel chemotherapeutic agent for malaria B Lell, R Ruangweerayut, J Wiesner, MA Missinou, A Schindler, ... Antimicrobial agents and chemotherapy 47 (2), 735-738, 2003 | 296 | 2003 |
| Fosmidomycin for malaria MA Missinou, S Borrmann, A Schindler, S Issifou, AA Adegnika, ... The Lancet 360 (9349), 1941-1942, 2002 | 283 | 2002 |
| The role of red blood cell polymorphisms in resistance and susceptibility to malaria B Lell, J May, RJ Schmidt-Ott, LG Lehman, D Luckner, B Greve, ... Clinical Infectious Diseases 28 (4), 794-799, 1999 | 246 | 1999 |
| Clindamycin as an antimalarial drug: review of clinical trials B Lell, PG Kremsner Antimicrobial agents and chemotherapy 46 (8), 2315-2320, 2002 | 234 | 2002 |
| Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria JFJ Kun, B Mordmüller, B Lell, LG Lehman, D Luckner, PG Kremsner The Lancet 351 (9098), 265-266, 1998 | 226 | 1998 |
| COVID-19 in Africa: Dampening the storm? M Mbow, B Lell, SP Jochems, B Cisse, S Mboup, BG Dewals, A Jaye, ... Science 369 (6504), 624-626, 2020 | 206 | 2020 |
| Merozoite surface antigen 1 and 2 genotypes and rosetting of Plasmodium falciparum in severe and mild malaria in Lambarene, Gabon JFT Kun, RJ Schmidt-Ott, LG Lehman, B Lell, D Luckner, B Greve, ... Transactions of the Royal Society of Tropical Medicine and Hygiene 92 (1 …, 1998 | 193 | 1998 |
| Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase … KP Asante, S Abdulla, S Agnandji, J Lyimo, J Vekemans, ... The Lancet infectious diseases 11 (10), 741-749, 2011 | 169 | 2011 |
| Plasma Interleukin-10: Tumor Necrosis Factor (TNF)—α Ratio Is Associated with TNF Promoter Variants and Predicts Malarial Complications J May, B Lell, AJF Luty, CG Meyer, PG Kremsner The Journal of infectious diseases 182 (5), 1570-1573, 2000 | 168 | 2000 |
Peter G. KremsnerProfessor for Tropical Medicine, Travel Medicine and Parasitology, University of Tübingen在 uni-tuebingen.de 的电子邮件经过验证
